Neal L. Benowitz, MD

Rennselaer Polytechnic Institute, Troy, NY
University of Rochester School of Medicine, Rochester, NY, MD, 1969, Medicine
Bronx Municipal Hospital Center, Bronx, New York, Intern and Resident, Internal Medicine, 1969-1971
Fellow in Clinical Pharmacology, Department of Medicine, University of California San Francisco, 1971-1972

• 1973-1972
  Clinical Instructor, Department of Medicine, University of California San Francisco
• 1975-1972
  Director, Drug Detoxification Unit, San Francisco General Hospital, San Francisco, California
• 1974-present
  Member of Staff, Medical Service, San Francisco General Hospital, San Francisco, California
• 1979-present
  Associate Medical Director, San Francisco Bay Area Regional Poison Center, San Francisco, CA
• 1974-1982
  Asst. Professor, Depts of Medicine and Psychiatry, University of Calif-ornia San Francisco, San Francisco, CA
• 1981-1982
  Assoc. Professor, Depts of Medicine and Psychiatry, University of California San Francisco, San Francisco, CA
• 1987-present
  Professor, Departments of Medicine, Psychiatry and Pharmacy, University of California San Francisco, San Francisco, California
• 1983-present
  Chief, Division Clinical Pharmacology and Experimental Therapeutics, University of California San Francisco
• 1994-2010
  Vice Chair, Department of Biopharmaceutical Sciences, University of California, San Francisco
• 2004-present
  Professor of Medicine, Biopharmaceutical Sciences, Psychiatry and Clinical Pharmacy, University of California, San Francisco

• Oscar B. Hunter Award
• Ove Ferno Award
• 2002
• UCSF Annual Distinguished Clinical Research Lecturer
• Rawls Palmer Award for Progress in Medicine
• Alton Ochsner Award Relating Smoking and Health
• 1994-2002
• NIDA Merit Award
• American Board of Internal Medicine (Diplomate, 1968)
• American Board of Medical Toxicology
• American Board of Clinical Pharmacology
• American Federation for Clinical Research (President 1996 to 1997)
• American Society for Clinical Inves-tigation
• American Society of Clinical Pharma-cology and Therapeutics
• American Society for Pharmacology and Experimental Therapeutics
• Association of American Physicians
• Society for Research on Nicotine and Tobacco (President, 1996-1997)

• Stepanov I, Hecht SS, Lindgren B, Jacob P, 3rd, Wilson M, Benowitz NL. Relationship of human toenail nicotine, cotinine, and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol to levels of these biomarkers in plasma and urine. Cancer Epidemiol Biomarkers Prev 2007;16:1382-6.
• Rubinstein ML, Benowitz NL, Auerback GM, Moscicki AB. Rate of nicotine metabolism and withdrawal symptoms in adolescent light smokers. Pediatrics 2008;122:e643-7. PMC2722964
• Rigotti NA, Pipe AL, Benowitz NL, Arteaga C, Garza D, Tonstad S. Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial. Circulation 2010;121:221-9.
• Goniewicz ML, Havel CM, Peng MW, Jacob P, 3rd, Dempsey D, Yu L, et al. Elimination kinetics of the tobacco-specific biomarker and lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol. Cancer Epidemiol Biomarkers Prev 2009;18:3421-5. PMC2804843
• Gan Q, Yang J, Yang G, Goniewicz M, Benowitz NL, Glantz SA. Chinese "herbal" cigarettes are as carcinogenic and addictive as regular cigarettes. Cancer Epidemiol Biomarkers Prev 2009;18:3497-501. PMC2789338
• Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, et al. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Hum Mol Genet 2008;17:2834-48. PMC2525499
• Benowitz NL, Schultz KE, Haller CA, Wu AH, Dains KM, Jacob P, 3rd. Prevalence of smoking assessed biochemically in an urban public hospital: a rationale for routine cotinine screening. Am J Epidemiol 2009;170:885-91. PMCID: PMC2765360
• Benowitz NL, Hukkanen J, Jacob P, 3rd. Nicotine chemistry, metabolism, kinetics and biomarkers. Handb Exp Pharmacol 2009:29-60.
• Benowitz NL, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P, 3rd. Nicotine and carcinogen exposure with smoking of progressively reduced nicotine content cigarette. Cancer Epidemiol Biomarkers Prev 2007;16:2479-85.
• Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P, 3rd. Progressive commercial cigarette yield reduction: biochemical exposure and behavioral assessment. Cancer Epidemiol Biomarkers Prev 2009;18:876-83. PMC2802575
• Benowitz NL, Dains KM, Dempsey D, Herrera B, Yu L, Jacob P, 3rd. Urine nicotine metabolite concentrations in relation to plasma cotinine during low-level nicotine exposure. Nicotine Tob Res 2009;11:954-60. PMC2734286
• Benowitz NL, Bernert JT, Caraballo RS, Holiday DB, Wang J. Optimal serum cotinine levels for distinguishing cigarette smokers and nonsmokers within different racial/ethnic groups in the United States between 1999 and 2004. Am J Epidemiol 2009;169:236-48.
• Benowitz NL. Pharmacology of nicotine: addiction, smoking-induced disease, and therapeutics. Annu Rev Pharmacol Toxicol 2009;49:57-71.
• Benowitz NL. Clinical pharmacology of nicotine: implications for understanding, preventing, and treating tobacco addiction. Clin Pharmacol Ther 2008;83:531-41.
• Benowitz NL. Neurobiology of nicotine addiction: implications for smoking cessation treatment. Am J Med 2008;121:S3-10.